202 related articles for article (PubMed ID: 37760847)
1. Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines.
Lefebvre C; Pellizzari S; Bhat V; Jurcic K; Litchfield DW; Allan AL
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760847
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
3. How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics.
Jain AP; Radhakrishnan A; Pinto S; Patel K; Kumar M; Nanjappa V; Raja R; Keshava Prasad TS; Mathur PP; Sidransky D; Chatterjee A; Gowda H
OMICS; 2021 Sep; 25(9):605-616. PubMed ID: 34432535
[TBL] [Abstract][Full Text] [Related]
4. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
[TBL] [Abstract][Full Text] [Related]
5. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
6. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
Cancer Metab; 2017; 5():6. PubMed ID: 28852500
[TBL] [Abstract][Full Text] [Related]
7. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
[TBL] [Abstract][Full Text] [Related]
8. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.
Sohn J; Liu S; Parinyanitikul N; Lee J; Hortobagyi GN; Mills GB; Ueno NT; Gonzalez-Angulo AM
J Cancer; 2014; 5(9):745-53. PubMed ID: 25368674
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.
Bartholomeusz C; Yamasaki F; Saso H; Kurisu K; Hortobagyi GN; Ueno NT
J Cancer; 2011; 2():435-42. PubMed ID: 21850211
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
12. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
13. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
[TBL] [Abstract][Full Text] [Related]
14. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
15.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
16. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
17. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Tabara K; Kanda R; Sonoda K; Kubo T; Murakami Y; Kawahara A; Azuma K; Abe H; Kage M; Yoshinaga A; Tahira T; Hayashi K; Arao T; Nishio K; Rosell R; Kuwano M; Ono M
PLoS One; 2012; 7(7):e41017. PubMed ID: 22815900
[TBL] [Abstract][Full Text] [Related]
18. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Sano T; Takeuchi S; Nakagawa T; Ishikawa D; Nanjo S; Yamada T; Nakamura T; Matsumoto K; Yano S
Int J Cancer; 2013 Jul; 133(2):505-13. PubMed ID: 23319394
[TBL] [Abstract][Full Text] [Related]
19. Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression.
Suárez-Arroyo IJ; Rios-Fuller TJ; Feliz-Mosquea YR; Lacourt-Ventura M; Leal-Alviarez DJ; Maldonado-Martinez G; Cubano LA; Martínez-Montemayor MM
J Cancer; 2016; 7(5):500-11. PubMed ID: 26958085
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
